Skip to main content
SpringerLink
Log in

Fertility Preserving Options in Endometrial Cancer

  • Chapter
  • First Online:
Recent Advances in Endometrial Cancer

  • 355 Accesses

Abstract

Endometrial cancer is increasingly been diagnosed in women less than 40 years who are desirous of fertility preservation. These are usually type 1 well differentiated tumors with good prognosis. Endometrial biopsy and Magnetic resonance imaging are important for treatment palnning. Conservative mangement may be offered in women with grade 1 tumors confined to endometrium, with no lymphovascular space invasion and extrauterine disease. Progestins including Medroxy preogesterone acetate, megesterol acetate are used for treatment. All efforts should be made for conception once histological remmision is achieved.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Endometrial cancer statistics. https://www.wcrf.org/dietandcancer/cancer-trends/endometrial-cancer-statistics. Accessed 23 October 2019.

  2. Cancer today: data visualization tool for exploring the global cancer burden in 2018. http://gco.iarc.fr/today/home. Accessed 23 October 2019.

  3. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016;387:1094–108.

    PubMed  Google Scholar 

  4. Howlader N, et al. SEER Cancer Statistics Review, 1975-2008. 2011 [cited 2011; based on November 2010 SEER data submission]. http://seer.cancer.gov/csr/1975_2008/

  5. Benshushan A. Endometrial adenocarcinoma in young patients: evaluation and fertility-preserving treatment. Eur J Obstet Gynecol Reprod Biol. 2004 Dec 1;117(2):132–7.

    PubMed  Google Scholar 

  6. Schmid D, Behrens G, Keimling M, Jochem C, Ricci C, Leitzmann M. A systematic review and meta-analysis of physical activity and endometrial cancer risk. Eur J Epidemiol. 2015;30(5):397–412.

    CAS  PubMed  Google Scholar 

  7. Aaltonen MH, Staff S, Mecklin JP, Pylvänäinen K, Mäenpää JU. Comparison of lifestyle, hormonal and medical factors in women with sporadic and lynch syndrome-associated endometrial cancer: a retrospective case-case study. Mol Clin Oncol. 2017;6(5):758–64.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Dashti SG, Chau R, Ouakrim DA, Buchanan DD, Clendenning M, Young JP, et al. Female hormonal factors and the risk of endometrial cancer in lynch syndrome. JAMA. 2015;314:61–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Gupta S, Provenzale D, Regenbogen SE, et al. NCCN guidelines insights: genetic/familial high-risk assessment: colorectal. Version 3.2017. J Natl Compr Cancer Netw. 2017;15:1465–75.

    CAS  Google Scholar 

  10. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(5):748–58.

    PubMed  PubMed Central  Google Scholar 

  11. Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, et al. Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(2):170–99.

    Google Scholar 

  12. Rodolakis A, Biliatis I, Morice P, Reed N, Mangler M, Kesic V, Denschlag D. European society of gynecological oncology task force for fertility preservation: clinical recommendations for fertility-sparing management in young endometrial cancer patients. Int J Gynecol Cancer. 2015;25(7):1258–65.

    PubMed  Google Scholar 

  13. Larson DM, Johnson KK, Broste SK, Krawisz BR, Kresl JJ. Comparison of D&C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer. Obstet Gynecol. 1995;86(1):38–42.

    CAS  PubMed  Google Scholar 

  14. Leitao MM Jr, Kehoe S, Barakat RR, et al. Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol. 2009;113:105–8.

    PubMed  Google Scholar 

  15. van Dongen H, de Kroon CD, Jacobi CE, Trimbos JB, Jansen FW. Diagnostic hysteroscopy in abnormal uterine bleeding: a systematic review and metaanalysis. BJOG. 2007;114(6):664–75.

    PubMed  Google Scholar 

  16. Ceci O, Bettocchi S, Pellegrino A, Impedovo L, Di VR, Pansini N. Comparison of hysteroscopic and hysterectomy findings for assessing the diagnostic accuracy of office hysteroscopy. Fertil Steril. 2002;78(3):628–31.

    PubMed  Google Scholar 

  17. Kaneda S, Fujii S, Fukanaga T, et al. Myometrial invasion by endometrial carcinoma: evaluation with 3.0T MR imaging. Abdom Imaging. 2011;36:612–8.

    PubMed  Google Scholar 

  18. Vasconcelos C, Félix A, Cunha TM. Preoperative assessment of deep myometrial and cervical invasion in endometrial carcinoma: comparison of magnetic resonance imaging and histopathologic evaluation. J Obstet Gynaecol. 2007;27:65–70.

    CAS  PubMed  Google Scholar 

  19. Kim SH, Kim HD, Song YS, Kang SB, Lee HP. Detection of deep myometrial invasion in endometrial carcinoma: comparison of transvaginal ultrasound, CT, and MRI. J Comput Assist Tomogr. 1995;19(5):766–72.

    CAS  PubMed  Google Scholar 

  20. Selman TJ, Mann CH, Zamora J, et al. A systematic review of tests for lymph node status in primary endometrial cancer. BMC Womens Health. 2008;8:8.

    PubMed  PubMed Central  Google Scholar 

  21. Yang S, Thiel KW, Leslie KK. Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab. 2011;22:145–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Hahn H-S, Yoon S-G, Hong J-S, et al. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer. 2009;19:1068–73.

    PubMed  Google Scholar 

  23. McKenzie ND, Kennard JA, Ahmad S. Fertility preserving options for gynecologic malignancies: a review of current understanding and future directions. Crit Rev Oncol Hematol. 2018;132:116–24.

    PubMed  Google Scholar 

  24. Corfman PA. Labeling guidance text for progestin-only oral contraceptives. Contraception. 1995;52:71–6.

    Google Scholar 

  25. Chen X. The current situation of the levonorgestrel intrauterine system (LNG-IUS) in conservative treatment for patients with early-stage endometrial cancer and atypical hyperplasia. J Gynecol Oncol. 2019;30(4):e79.

    PubMed  PubMed Central  Google Scholar 

  26. Luo L, Luo B, Zheng Y, Zhang H, Li J, Sidell N. Oral and intrauterine progestogens for atypical endometrial hyperplasia. Cochrane Database Syst Rev. 2018;12:CD009458.

    PubMed  Google Scholar 

  27. Abu Hashim H, Ghayaty E, El Rakhawy M. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials. Am J Obstet Gynecol. 2015 Oct;213(4):469–78.

    CAS  PubMed  Google Scholar 

  28. Pal N, Broaddus RR, Urbauer DL, Balakrishnan N, Milbourne A, Schmeler KM, et al. Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device. Obstet Gynecol. 2018;131(1):109–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Leone Roberti Maggiore U, Martinelli F, Dondi G, Bogani G, Chiappa V, Evangelista MT, et al. Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study. J Gynecol Oncol. 2019;30(4):e57.

    PubMed  PubMed Central  Google Scholar 

  30. Minig L, Franchi D, Boveri S, et al. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Ann Oncol. 2011;22:643–9.

    CAS  PubMed  Google Scholar 

  31. Mazzon I, Corrado G, Masciullo V, Morricone D, Ferrandina G, Scambia G. Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril. 2010;93:1286–9.

    PubMed  Google Scholar 

  32. Casadio P, Guasina F, Talamo MR, Paradisi R, Morra C, Magnarelli G, et al. Conservative hysteroscopic treatment of stage I well differentiated endometrial cancer in patients with high surgical risk: a pilot study. J Gynecol Oncol. 2019;30(4):e62.

    PubMed  PubMed Central  Google Scholar 

  33. Alonso S, Castellanos T, Lapuente F, Chiva L. Hysteroscopic surgery for conservative management in endometrial cancer: a review of the literature. Ecancermedicalscience. 2015;9:505.

    PubMed  PubMed Central  Google Scholar 

  34. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO endometrial consensus conference working group. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Radiother Oncol. 2015 Dec;117(3):559–81.

    PubMed  Google Scholar 

  35. Arora V, Quinn MA. Endometrial cancer. Best Pract Res Clin Obstet Gynaecol. 2012;26(3):311–24.

    PubMed  Google Scholar 

  36. Ushijima K, Yahata H, Yoshikawa H, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol. 2007;25:2798–803.

    CAS  PubMed  Google Scholar 

  37. Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012;125:477.

    CAS  PubMed  Google Scholar 

  38. Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012;207(4):266.e1–12.

    Google Scholar 

  39. Park JY, Lee SH, Seong SJ, Kim DY, Kim TJ, Kim JW, et al. Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin. Gynecol Oncol. 2013;129(1):7–11.

    CAS  PubMed  Google Scholar 

  40. Peiretti M, Congiu F, Ricciardi E, Maniglio P, Mais V, Angioni S. Conservative treatment for well-differentiated endometrial cancer: when and why it should be considered in young women. Ecancermedicalscience. 2019;13:892.

    PubMed  PubMed Central  Google Scholar 

  41. Zaino R, Whitney C, Brady MF, et al. Simultaneously detected endometrial and ovarian carcinomas: a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. Gynecol Oncol. 2001;83:355–62.

    CAS  PubMed  Google Scholar 

  42. Richter CE, Qian B, Martel M, et al. Ovarian preservation and staging in reproductive-age endometrial cancer patients. Gynecol Oncol. 2009;114:99–104.

    PubMed  Google Scholar 

  43. Wright JD, Buck AM, Shah M, Burker WM, Schiff PR, Herzog TJ. Safety of ovarian preservation in premenopausal women with endometrial cancer. J Clin Oncol. 2009;27:1214–9.

    PubMed  Google Scholar 

  44. Elizur SE, Beiner ME, Korach J, Weiser A, Ben-Baruch G, Dor J. Outcome of in vitro fertilization treatment in infertile women conservatively treated for endometrial adenocarcinoma. Fertil Steril. 2007;88:1562–7.

    PubMed  Google Scholar 

  45. Tong XM, Lin XN, Jiang HF, Jiang LY, Zhang SY, Liang FB. Fertility-preserving treatment and pregnancy outcomes in the early stage of endometrial carcinoma. Chin Med J. 2013;126(15):2965–71.

    PubMed  Google Scholar 

  46. Yamagami W, Susumu N, Ichikawa Y, et al. Thirty-four successful cases of pregnancy following fertility-preserving hormonal therapy for endometrial cancer. Gynecol Oncol. 2012;125:S5.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Obstetrics and Gynecology, UCMS & GTB Hospital, Delhi, India

    Bindiya Gupta

Authors
  1. Bindiya Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Obstetrics & Gynecology, Babu Jagjivan Ram Memorial Hospital, New Delhi, India

    Sumita Mehta

  2. Obstetrics and Gynecology, UCMS & GTB Hospital, Delhi, India

    Bindiya Gupta

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gupta, B. (2020). Fertility Preserving Options in Endometrial Cancer. In: Mehta, S., Gupta, B. (eds) Recent Advances in Endometrial Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-15-5317-2_10

Download citation

  • DOI: https://doi.org/10.1007/978-981-15-5317-2_10

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-15-5316-5

  • Online ISBN: 978-981-15-5317-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation